ArticleDiabetes & vascular disease research
Clinical significance of LINC00893 and miR-103a-3p in type 2 diabetes mellitus patients with coronary heart disease.
Article in Diabetes & vascular disease research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundCoronary heart disease (CHD) is a prevalent complication associated with type 2 diabetes mellitus (T2DM), and the incidence of T2DM with CHD has seen a steady rise over the preceding years.ObjectiveTo investigate the altered expression of LINC00893 and miR-103a-3p in T2DM and T2DM with CHD, as well as to assess their clinical significance in T2DM-CHD.MethodsThe LINC00893 and miR-103a-3p expression was detected by RT-qPCR. ROC curves were used to analyze the diagnostic significance of LINC00893 and miR-103a-3p in T2DM patients with CHD. The Kaplan-Meier curve was used to analyze the prognostic significance of LINC00893 in the occurrence of Major Adverse Cardiovascular Events (MACEs) of T2DM with CHD patients. Dual-luciferase reporter assay was used to confirm the regulatory relationship between LINC00893 and miR-103a-3p.ResultLINC00893 and miR-103a-3p were down-regulated and up-regulated in T2DM with CHD patients, respectively and had diagnostic value in T2DM with CHD patients. In addition, patients with low levels of LINC00893 are more likely to develop MACE, and LINC00893 could regulate the expression of miR-103a-3p.ConclusionLINC00893 may affect disease progression in T2DM patients with CHD by regulating miR-103a-3p.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.